Pérez-Cortés Villalobos A, Rotstein C.
Mycobacterium mucogenicum and
Mycobacterium neoaurum bacteremia in immunocompromised hosts.
JOURNAL OF THE ASSOCIATION OF MEDICAL MICROBIOLOGY AND INFECTIOUS DISEASE CANADA = JOURNAL OFFICIEL DE L'ASSOCIATION POUR LA MICROBIOLOGIE MEDICALE ET L'INFECTIOLOGIE CANADA 2021;
6:55-62. [PMID:
36340214 PMCID:
PMC9612434 DOI:
10.3138/jammi-2020-0025]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/06/2020] [Accepted: 09/16/2020] [Indexed: 06/16/2023]
Abstract
BACKGROUND
Mycobacterium mucogenicum and Mycobacterium neoaurum are infrequent causes of bacteremia in humans. When they are isolated from blood, it is not unusual for them to initially be considered contaminants.
METHODS
A retrospective chart review of patients diagnosed with M. mucogenicum and M. neoaurum bacteremia from January 1998 to December 2018 was conducted at the University Health Network, Toronto, Ontario, Canada.
RESULTS
We identified 28 patients who had bacteremia caused by these organisms. These patients were primarily immunocompromised, had chronically indwelling vascular access devices, or used intravenous drugs. For 29% of the patients, the isolation of these mycobacteria was considered colonization, whereas 82% of the patients received antimicrobial therapy and 95% had the central line removed.
CONCLUSIONS
The removal of the vascular access device and treatment with either single or combination antimicrobial therapy produced successful outcomes for people with these infections.
Collapse